Navigation Links
NeuroVive Pharmaceutical AB Publishes 2016 Annual Report
Date:3/23/2017

LUND, Sweden, Mar 23, 2017 /PRNewswire/ --

NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced that the English version of the Annual report for 2016 is now available on the company's website www.neurovive.com

About NeuroVive

NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine. The company is committed to the discovery and development of medicines that preserve mitochondrial integrity and function in areas of unmet medical need. The company's strategy is to take drugs for rare diseases through clinical development and into the market. The strategy for projects within larger indications outside the core focus area is out-licensing in the preclinical phase. NeuroVive enhances the value of its projects in an organization that includes strong international partnerships and a network of mitochondrial research institutions, as well as expertise with capacities within drug development and production.

NeuroVive has a project in early clinical phase II development for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). NeuroSTAT has orphan drug designation in Europe and in the US. The R&D portfolio consists of several late stage research programs in areas ranging from genetic mitochondrial disorders to cancer and metabolic diseases such as NASH.

NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).

For investor relations and media questions, please contact:

Cecilia Hofvander
NeuroVive
Tel: +46-(0)46-275-62-21 or ir@neurovive.com

NeuroVive Pharmaceutical AB (publ)

Medicon Village
SE-223 81 Lund, Sweden
Tel: +46-(0)46-275-62-20 (switchboard)
www.neurovive.com

This information is information that NeuroVive Pharmaceutical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:35 a.m. CET on March 23, 2017.

This information was brought to you by Cision http://news.cision.com
http://news.cision.com/neurovive-pharmaceutical/r/neurovive-pharmaceutical-ab-publishes-2016-annual-report,c2221355

The following files are available for download:

http://mb.cision.com/Main/6574/2221355/646778.pdf

NeuroVive Pharmaceutical AB publishes 2016 Annual report

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/neurovive-pharmaceutical-ab-publishes-2016-annual-report-300428340.html


'/>"/>
SOURCE NeuroVive Pharmaceutical
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Notice of Annual General Meeting of Shareholders in NeuroVive Pharmaceutical AB
2. NeuroVive Appoints Recognized Scientific Advisors and Enters Research Agreements in NASH and Hepatocellular Carcinoma
3. NeuroVive Redirects Research Resources From Asian Subsidiary to Parent
4. NeuroVive Signs Mitochondrial Medicine Research Agreement With US key Opinion Leader
5. NeuroVive Signs Collaboration Agreement With Karolinska Institutet
6. Update - Ampio Pharmaceuticals Provides Corporate Update
7. China Pharmaceutical Packaging Industry Report, 2016-2021
8. Global Pharmaceutical Packaging Market to Reach $129.8 Billion by 2025 - Rising Demand for Primary Pharmaceutical Packaging in Emerging Markets - Research and Markets
9. Imprimis Pharmaceuticals to Raise $3.1 Million in Registered Direct Offering
10. InDex Pharmaceuticals Concludes Well Attended Investigators Meeting for the Phase IIb Study Conduct
11. Jazz Pharmaceuticals Announces Positive Results from the Phase 3 TONES 3 and TONES 4 Studies of JZP-110 in Patients with Obstructive Sleep Apnea
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and ... financial results for the third quarter of 2017 on ... conference call on that day with the investment community ... The conference call will begin at 9 ... can access a live webcast of the conference call ...
(Date:10/2/2017)... , Oct. 2, 2017 Halo Labs announces the European ... system called the HORIZON at MIBio 2017 in Cambridge, ... and visible particulate matter in biopharmaceutical samples with unprecedented speed and ... the novel technique Backgrounded Membrane Imaging. ... The HORIZON subvisible particle analysis system ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: ... “America On The Brink” is the creation of published author, William Nowers. ... As a WWII veteran, he spent thirty years in the Navy. Following ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
(Date:10/12/2017)... ... October 12, 2017 , ... On Saturday, October 21, ... relay – Miles by Moonlight to raise money for the American Heart Association Heart ... , Teams will work together to keep their treadmills moving for 5 hours. ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):